Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Liabilities and Shareholders Equity (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $383.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 18.72% year-over-year to $383.5 million, compared with a TTM value of $1.4 billion through Dec 2025, up 6.96%, and an annual FY2025 reading of $383.5 million, up 18.72% over the prior year.
  • Liabilities and Shareholders Equity was $383.5 million for Q4 2025 at Xeris Biopharma Holdings, up from $370.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $383.5 million in Q4 2025 and bottomed at $131.3 million in Q3 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $319.8 million, with a median of $325.4 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 130.85% in 2022, then fell 6.36% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $304.4 million in 2021, then rose by 13.2% to $344.5 million in 2022, then dropped by 6.36% to $322.6 million in 2023, then increased by 0.14% to $323.1 million in 2024, then increased by 18.72% to $383.5 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for XERS at $383.5 million in Q4 2025, $370.2 million in Q3 2025, and $334.7 million in Q2 2025.